Trial · NCT05070260
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
NCT05070260, Phase 2, Phase 3, Completed, Acticor Biotech
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo. Trials, record NCT05070260. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05070260
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
- NCT number
- NCT05070260
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 438 participants, actual
- Lead sponsor
- Acticor Biotech
- Conditions
- Acute Ischemic Stroke
- Interventions
- Intravenous glenzocimab (ACT017) 1000 mg, Intravenous Placebo
- First posted
- 2021-10-07
- Last updated
- 2024-07-03
Source ClinicalTrials.gov
Registered outcomes77
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Binary Poor Outcome on the mRS defined by a score of 4-6 (versions 0-3) | Day 90 | To show the efficacy of glenzocimab vs. placebo, on the "poor outcome" defined as a mRS score of 4-6 (vs 0-3) assessed at Day 90 |
| Secondary | Key Secondary Efficacy Endpoint - mRS | Day 90 | Binary "Favorable Outcome" on the mRS defined by a score of 0-2 (versus 3-6) |
| Secondary | Mortality | Day 90 | All cause mortality |
| Secondary | mRS | Day 90 | To assess the favorable responses defined as mRS score of 0-1 |
| Secondary | mRS | Day 90 | To assess the favorable responses defined as mRS score of 5-6 |
| Secondary | Ordinal mRS | Day 90 | To assess the shift analysis |
| Secondary | Utility Weighted mRS | Day 90 | To assess the utility weighted mRS (UW-mRS) |
| Secondary | All cause mortality | 72 hours | To assess all cause mortality |
| Secondary | ICHs | 72 hours | Symptomatic and non-symptomatic ICHs |
| Secondary | Neurological Status Change as assessed by NIHSS value compared to pre-IVT value | 24 hours | Response defined by a relative decrease (%) in NIHSS value at 24 hours compared to pre-IVT value higher than 30%. Relative change (%) in NIHSS value at 24 hrs compared to pre-IVT value |
1 to 10 of 77Source ClinicalTrials.gov
See all 77 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05070260
GET https://conductscience.org/api/trials/v1/NCT05070260/registered?page=2